|Day Low/High||35.55 / 36.30|
|52 Wk Low/High||33.88 / 64.50|
Shares were down 8% Thursday.
Amazon's acquisition of PillPack is hitting traditional pharmacies.
These stocks are selling at historically low earnings multiples, but have raised their dividends for decades.
Stocks traded in a different pattern Wednesday, as big tech names dominated.
I know there's plenty of irony to go around for this once great manufacturer to be replaced in the Dow by a drug store chain.
Drugstore giant's charts were showing positive signs even before its inclusion in the Dow Jones Industrial Average.
GE is getting tossed from the index, after 111 consecutive years.
These are the stories pushing futures higher ahead of Wednesday's opening bell.
The drugstore chain's price to fair value has not been this favorable since the Crash of 2008-2009.
Theranos, once a Silicon Valley unicorn promising investors and partners like Walgreens a simple blood-testing solution, is a cautionary tale for biotech investors.
Few companies can match CVS' long-term record and top-quality corporate metrics.
If anyone can sell it to antitrust regulators, T-Mobile CEO John Legere can.
Better-than-expected earnings will help soothe market jitters in the second quarter.
Charts suggest there may be hope for Walgreens bulls.
The keys? Preparation, Discipline and Plan of Action.
Volume and other indicators suggest more weakness ahead.
The 'dash 1000' is the largest Airbus A350 the company has every produced.
As Albertsons prepares to bring a significant piece of Rite Aid into its family, we took a look back at how the grocer became the mega chain it is today.
Welcome back from the long weekend, Wall Street. Here's what you must know.
The Wall Street Journal reported that Walgreens Boots Alliance has contacted AmerisourceBergen about a possible takeover.
With Dow futures pointed south, it looks to be another interesting day on Wall Street. Here's what you need to know.
The rally from the late October low has been stronger than other rallies and suggests that the rally in WBA is not over just yet.
We see a notable shift away from traditional large-cap pharmaceutical stocks to more specialized niches.